<DOC>
	<DOCNO>NCT00361166</DOCNO>
	<brief_summary>The primary purpose study determine whether combination ACP-103 ( study medication ) either haloperidol risperidone show antipsychotic efficacy safe well tolerate . Further purpose study determine whether ACP-103 , combination either haloperidol risperidone , enhance antipsychotic effectiveness , demonstrate effectiveness negative symptom , improve motoric tolerability , safe well tolerate . This seven-week study ( one week screen six week study medication ) total 400 patient meet entrance criterion randomly assign receive one five group study treatment either low dose haloperidol plus ACP-103 , low dose haloperidol plus placebo ( substance similar sugar pill ) , low dose risperidone plus ACP-103 , low dose risperidone plus placebo , high dose risperidone plus placebo . The study begin three seven day drug-free period follow six week stable daily dosage study medication . Study subject treat hospital in-patients screen first 14 day study . Study subject closely monitor throughout study .</brief_summary>
	<brief_title>Antipsychotic Motor Effects ACP-103 When Administered Combination With Haloperidol Risperidone</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>male female subject age 1865 diagnose schizophrenia experience acute exacerbation psychosis prior response antipsychotic therapy within previous 3 year female subject must nonchildbearing potential must comply doublebarrier protection method conception ability subject caregiver legally authorize representative provide inform consent subject must hospitalize screening must willing remain hospital least 14 day baseline must comply study event completion study inability subject caregiver legally authorize representative provide consent female subject pregnant breast feeding subject concurrent mental illness disability subject consider danger others recent use certain antipsychotic medication might interfere study 's medication abnormal clinical laboratory value presence , recent history , serious medical condition drug abuse likely allergy sensitivity ACP103 , haloperidol , risperidone , base know allergy drug class subject participate prior clinical trial ACP103 subject judge Principal Investigator inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>psychosis</keyword>
	<keyword>delusion</keyword>
	<keyword>hallucination</keyword>
</DOC>